Jeevan Puthiamadathil @jeevanpmd

Thoracic Oncologist, Division of Oncology 2, @FDAOncology; opinions are my own | @theNCI, @gtown_medres @GUMedicine Washington, DC Joined April 2021

Tweets

4
Followers

81
Following

144
Likes

32

FDA Oncology @FDAOncology

2 years ago

Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via @TheCancerLetter open access article.

The Cancer Letter @TheCancerLetter

2 years ago

Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via @TheCancerLetter open access article.

3 25 41 28K 8

0 19 23 15K 2

Stephen V Liu, MD @StephenVLiu

3 years ago

Phase II @CDNCancerTrials IND.227 trial @JTOonline. Phase II study compared chemo (platinum + pemetrexed) to chemo + pembro to pembro alone in pts with mesothelioma. Pembro + chemo offered higher RR (47% vs 19%) and OS (20m vs 9m) than chemo alone. jto.org/article/S1556-…

1 14 33 4K 2

FDA Oncology @FDAOncology

3 years ago

Drs. Ladi Akinboro @LadiAkinboro, Harpreet Singh @harpreet_md and Jeevan Puthiamadathil @jeevanpmd of FDA Division of Oncology 2 attending the @IASLC Targeted Therapies of Lung Cancer meeting in Santa Monica earlier this week. #TTLC23 #OCEWorks4U #OCECareers #EndCancerAsWeKnowIt